GlassScriptPhysician profile
Linda Kessinger
NPI 1487634275
$2,904.53
in general payments reported to CMS, 2019-2025
32 companies · $906 in 2025
The $906 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $64.44 · 2021: $65.68 · 2022: $137 · 2023: $374 · 2024: $920 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,200.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,020.14 | 2022-2025 | |
| Novo Nordisk INC | $293.69 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $151.05 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $124.04 | 2019-2024 | |
| Biogen, INC. | $119.78 | 2025 | Zurzuvae |
| Sage Therapeutics, LLC | $118.00 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $97.37 | 2023-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.35 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.84 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $80.25 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.48 | 2022-2025 | Xifaxan |
| Echosens North America, INC. | $75.57 | 2025 | Fibroscan |
| Lilly USA, LLC | $72.06 | 2022-2024 | Jardiance, Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $67.46 | 2019-2020 | |
| Amgen INC. | $63.03 | 2019-2024 | Repatha, Otezla |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $46.58 | 2019 | |
| Dexcom, INC. | $38.07 | 2024-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $37.04 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $29.77 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $28.04 | 2019-2024 | Breztri |
| Phathom Pharmaceuticals, INC. | $25.43 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $23.80 | 2020 | |
| Vanda Pharmaceuticals INC. | $22.30 | 2025 | Fanapt |
| Organon LLC | $19.99 | 2022 | |
| Insulet Corporation | $14.84 | 2024 | Omnipod |
| Hologic Sales and Service, LLC | $14.74 | 2024 | Aptima |
| Biohaven Pharmaceutical Holding Company LTD. | $14.26 | 2022 | |
| Abbott Laboratories | $13.91 | 2023 | Freestyle Libre 3 |
| Lundbeck LLC | $12.90 | 2023 | Vyepti |
| Agile Therapeutics, INC. | $12.41 | 2022 | |
| Allergan, INC. | $11.66 | 2019 | |
| Corium, LLC | $7.68 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Kessinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.